Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions

NCT00694187
View directory record Official record
Conditions
Short Term Treatment of Insomnia
Interventions
Zaleplon
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

NCT05665283
View directory record Official record
Conditions
Bioequivalency
Interventions
Ensartinib Hydrochloride
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

NCT01962922
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Tacrolimus -IR
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

NCT03482453
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

NCT01116622
View directory record Official record
Conditions
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Interventions
Bexarotene (Targretin®), Erlotinib (Tarceva™)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation

NCT02107157
View directory record Official record
Conditions
Facial Rejuvenation
Interventions
755nm Laser with Cap Array
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 20, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

NCT04764357
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05428033
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

NCT03801148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 20, 2026, 1:04 AM EDT
Not listed Phase 1 Interventional

Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

NCT05681000
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Utidelone Capsule
Drug
Lead sponsor
Biostar Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 20, 2026, 1:04 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

NCT02065401
View directory record Official record
Conditions
Healthy
Interventions
Deferitazole (disodium salt, granule), Deferitazole (disodium salt, tablet), Deferitazole (magnesium hydroxide salt)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

NCT05503511
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

NCT01801735
View directory record Official record
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01698060
View directory record Official record
Conditions
Avian Influenza
Interventions
ND1.1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 3 Interventional

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

NCT00274560
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
20
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

NCT03247517
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 200mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 20, 2026, 1:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of a Nitrate Supplementation on Erectile Function

NCT06213077
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Nitric Oxide, Tadalafil, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
RHA Investments Ltd
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Results available

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

NCT03329001
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib Tablet, Niraparib Capsule
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Naproxen Capsules to Treat Dental Pain

NCT01229228
View directory record Official record
Conditions
Dental Pain
Interventions
Naproxen Test, Naprosyn, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

NCT07019064
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition

NCT01888328
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

NCT02792829
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 20, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

NCT06094712
View directory record Official record
Conditions
Healthy
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 20, 2026, 1:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 1:04 AM EDT